BioSpace News Archive

Replimune Group Inc., a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, announced that members of its executive team and Key Opinion Leaders will host an investor event to present updated data from the completed cohorts of the Phase 2 IGNYTE clinical trial in non-melanoma skin cancer and melanoma.

Qu Biologics Inc. is pleased to announce the closing of a USD$12M equity financing to enable expansion of Qu’s team, initiation of an additional three Phase 2 clinical studies, and the acceleration of Qu’s novel immunomodulation platform.

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported fourth quarter and full year 2021 financial results and provided a corporate update.

Arcutis Biotherapeutics, Inc. will host an Investor Day in Boston, MA on Monday, March 28, 2022 at 10:30 a.m. EDT.

Kazia Therapeutics Limited, a late stage, oncology-focused drug development company, is pleased to announce upcoming presentations at two international conferences.

ClearCut Medical Ltd., a developer of innovative, portable MRI systems for intraoperative margin assessment in cancer surgery, is pleased to announce the appointment of Hezi Himelfarb as CEO in conjunction with the company’s transition from a development stage to commercial stage company.

Arcuro Medical Ltd., a portfolio company of The Trendlines Group, announced the appointment of Dr. Phil Davidson as Medical Director and Chair of the Company’s Scientific Advisory Board.

Mileutis announced that a recent paper published in the Journal of Dairy Science on its Mileutis Imilac™ therapy provides results that support the use of Imilac™ bovine casein hydrolysate treatment as a valid alternative to antibiotics for the management of Mastitis: the leading problem of the dairy industry.

Pulmatrix, Inc. (NASDAQ: PULM), today announced positive top-line results of its recently completed Phase 1b clinical study of PUR1800, a narrow-spectrum kinase inhibitor (NSKI) administered as a dry powder for inhalation with iSPERSE™ for evaluation in patients with stable Chronic Obstructive Pulmonary Disease (COPD)

Primmune Therapeutics Presents Data Evaluating PRTX007 as an Antiviral at the 35th International Conference on Antiviral Research (ICAR).